➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Colorcon
Dow
McKesson
AstraZeneca

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TISAGENLECLEUCEL

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for tisagenlecleucel

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03570892 Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma Not yet recruiting Novartis Pharmaceuticals Phase 3 2018-10-26 This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immunochemotherapy.
NCT03628053 Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia Not yet recruiting Novartis Pharmaceuticals Phase 3 2019-01-17 This trial aims to compare the benefits and risks of tisagenlecleucel to blinatumomab or inotuzumab in adult patients with relapsed or refractory ALL. This trial investigates tisagenlecleucel as an additional treatment option for this patient population with high unmet medical need.
NCT03630159 Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients Recruiting Novartis Pharmaceuticals Phase 1 2018-09-04 A multi-center, open-label, phase Ib study to evaluate the safety and efficacy of the administration of tisagenlecleucel in combination with pembrolizumab in patients with r/r DLBCL who have received 2 or more lines of systemic therapy, including an anti-CD20 and anthracycline based chemotherapy and having failed to or are not candidates for ASCT. The study will consist of 2 parts: dose timing selection part and expansion part.
NCT03642626 MT2017-45 :CAR-T Cell Therapy for Heme Malignancies Not yet recruiting Masonic Cancer Center, University of Minnesota Phase 2 2018-12-01 This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately.
NCT03876028 Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients Not yet recruiting Novartis Pharmaceuticals Phase 1 2019-03-27 A multi-center, open-label, phase Ib study to evaluate the safety and tolerability of the administration of tisagenlecleucel in combination with ibrutinib in patients with r/r DLBCL who have received two or more lines of systemic therapy, including an anti-CD20 and anthracycline based chemotherapy, and who have progressed after or are not candidates for ASCT.
NCT04071366 A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy Not yet recruiting Incyte Corporation Phase 2 2020-01-01 The purpose of this study is to assess the safety and efficacy of oral administration of itacitinib once daily for the prevention of cytokine release syndrome (CRS) in male or female participants aged 12 years or older and who are planning to receive tisagenlecleucel or axicabtagene ciloleucel immune effector cell (IEC) therapy for any approved hematologic indication.
NCT04161118 Phase II Trial of TisaGenlecleucel (Kymriah®) in Elderly Patients With First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma Not yet recruiting Novartis Phase 2 2020-08-01 A phase II trial of TisaGenlecleucel (Kymriah®) in Elderly Patients with First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for tisagenlecleucel

Condition Name

Condition Name for tisagenlecleucel
Intervention Trials
Acute Lymphoblastic Leukemia 2
Diffuse Large B-cell Lymphoma 2
Cytokine Release Syndrome 1
Non-Hodgkin Lymphoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for tisagenlecleucel
Intervention Trials
Lymphoma, B-Cell 5
Lymphoma 4
Lymphoma, Large B-Cell, Diffuse 2
Precursor Cell Lymphoblastic Leukemia-Lymphoma 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for tisagenlecleucel

Trials by Country

Trials by Country for tisagenlecleucel
Location Trials
United States 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for tisagenlecleucel
Location Trials
Pennsylvania 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for tisagenlecleucel

Clinical Trial Phase

Clinical Trial Phase for tisagenlecleucel
Clinical Trial Phase Trials
Phase 3 2
Phase 2 3
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for tisagenlecleucel
Clinical Trial Phase Trials
Not yet recruiting 6
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for tisagenlecleucel

Sponsor Name

Sponsor Name for tisagenlecleucel
Sponsor Trials
Novartis Pharmaceuticals 4
University of Cologne 1
Novartis 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for tisagenlecleucel
Sponsor Trials
Industry 6
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Baxter
Dow
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.